Professional Documents
Culture Documents
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
SUMMARY:
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00002
Fmt 4701
Sfmt 4702
E:\FR\FM\15JYP2.SGM
15JYP2
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
these two pieces of equipment as a
single item with a price of $150,000.
CPT codes 88360 and 88361 have been
valued using this new price. The
equipment time values remain
unchanged.
The RUC recommendation for CPT
codes 88360 and 88361 included an
invoice for the Antibody Estrogen
Receptor monoclonal supply (SL493).
The submitted invoice has a price of
$694.70 per box of 50, or $13.89 per test.
We sought publically available
information regarding this supply and
identified numerous monoclonal
antibody estrogen receptors that appear
to be consistent with those
recommended by the specialty society,
at publicly available lower prices,
which we believe are more likely to be
typical since we assume that the typical
practitioner would seek the best price
available to the public. One example is
Estrogen Receptor Antibody (h-151)
[DyLight 405], priced at 100 tests per
box for $319. Therefore, we are
proposing to establish a new supply
code for Antibody Estrogen Receptor
monoclonal and price that item at
$3.19 each. We welcome comments
from stakeholders regarding this supply
item.
h. Nerve Teasing Preparations (CPT
Code 88362)
We are proposing to refine the
recommended clinical labor time for
Assist pathologist with gross specimen
examination including the following;
Selection of fresh unfixed tissue sample;
selection of tissue for formulant fixation
for paraffin blocking and epon blocking.
Reserve some specimen for additional
analysis from 10 minutes to 5 minutes.
We note that the 5 minutes includes 3
minutes for assisting the pathologist
with the gross specimen examination (as
listed in Table 6) and an additional 2
minutes for the additional tasks due to
the work taking place on a fresh
specimen.
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00097
Fmt 4701
Sfmt 4702
41781
E:\FR\FM\15JYP2.SGM
15JYP2
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00123
Fmt 4701
Sfmt 4702
41807
E:\FR\FM\15JYP2.SGM
15JYP2
41808
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00124
Fmt 4701
Sfmt 4702
E:\FR\FM\15JYP2.SGM
15JYP2
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
reporting for less than one year,
regardless of reporting mechanism.
After a measures first year in use, we
will evaluate the measure to see if and
when the measure is suitable for public
reporting.
Measures must be based on reliable
and valid data elements to be useful to
consumers. Therefore, for all proposed
measures available for public reporting,
including both group and individual EP
level measuresregardless of reporting
mechanism, only those proposed
measures that prove to be valid, reliable,
and accurate upon analysis and review
at the conclusion of data collection and
that meet the established public
reporting criteria of a minimum sample
size of 20 patients will be included on
Physician Compare. For information on
how we determine the validity and
reliability of data and other statistical
analyses we perform, refer to the CY
2015 PFS final rule with comment
period (79 FR 67764 through 79 FR
67765).
We will also continue to include an
indicator of which reporting mechanism
was used and to only include on the site
measures deemed statistically
comparable.2 We will continue to
publicly report all measures submitted
and reviewed and found to be
statistically valid and reliable in the
Physician Compare downloadable file.
However, not all of these measures
would necessarily be included on the
Physician Compare profile pages.
Consumer testing has shown profile
pages with too much information and
measures that are not well understood
by consumers can negatively impact a
consumers ability to make informed
decisions. Our analysis of the collected
measure data, along with consumer
testing and stakeholder feedback, will
determine specifically which measures
are published on Web site profile pages.
Statistical analyses, like those specified
above, will ensure the measures
included are statistically valid and
reliable and comparable across data
collection mechanisms. Stakeholder
feedback will help us to ensure that all
publicly reported measures meet current
clinical standards. When measures are
finalized in advance of the time period
in which they are collected, it is
possible that clinical guidelines can
change rendering a measure no longer
relevant. Publishing that measure can
lead to consumer confusion regarding
what best practices their health care
professional should be subscribing to.
2 By statistically comparable, CMS means that the
quality measures are analyzed and proven to
measure the same phenomena in the same way
regardless of the mechanism through which they
were collected.
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00125
Fmt 4701
Sfmt 4702
41809
E:\FR\FM\15JYP2.SGM
15JYP2
41810
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
TABLE 18SUMMARY OF PREVIOUSLY FINALIZED POLICIES FOR PUBLIC REPORTING ON PHYSICIAN COMPARE
Data
collection
year
Reporting mechanism(s)
2012 ...........
2013 ...............................
2012 ...........
WI ...................................
2013 ...........
2014 ...............................
2013 ...........
WI ...................................
2013 ...........
2014 ...........
2014 ...........
2014 ...........
2014 ...........
2014 ...........
2014 ...........
Registry ..........................
Include an indicator for satisfactory reporters under PQRS, successful eprescribers under eRx Incentive Program, and participants in the EHR
Incentive Program.
5 Diabetes Mellitus (DM) and Coronary Artery Disease (CAD) measures
collected via the WI for group practices reporting under PQRS with a
minimum sample size of 25 patients and Shared Savings Program
ACOs.
Include an indicator for satisfactory reporters under PQRS, successful eprescribers under eRx Incentive Program, and participants in the EHR
Incentive Program. Include an indicator for EPs who earn a PQRS Maintenance of Certification Incentive and EPs who report the PQRS Cardiovascular Prevention measures group in support of Million Hearts.
3 DM and 1 CAD measures collected via the WI for groups of 25 or more
EPs with a minimum sample size of 20 patients.
6 CAHPS for ACO summary survey measures for Shared Savings Program ACOs.
Include an indicator for satisfactory reporters under PQRS and participants
in the EHR Incentive Program. Include an indicator for EPs who earn a
PQRS Maintenance of Certification Incentive and EPs who report the
PQRS Cardiovascular Prevention measures group in support of Million
Hearts.
All measures reported via the WI, 13 EHR, and 16 registry measures for
group practices of 2 or more EPs reporting under PQRS with a minimum
sample size of 20 patients.
Include composites for DM and CAD, if available.
All measures reported by Shared Savings Program ACOs, including
CAHPS for ACO and claims based measures.
Up to 12 CAHPS for PQRS summary measures for groups of 100 or more
EPs reporting via the WI and group practices of 25 to 99 EPs reporting
via a CMS-approved certified survey vendor.
A sub-set of 20 PQRS measures submitted by individual EPs that align
with those available for group reporting via the WI and that are collected
through registry, EHR, or claims with a minimum sample size of 20 patients.
Measures from the Cardiovascular Prevention measures group reported by
individual EPs in support of Million Hearts with a minimum sample size
of 20 patients.
PO 00000
VerDate Sep<11>2014
Jkt 235001
Frm 00126
Fmt 4701
Sfmt 4702
E:\FR\FM\15JYP2.SGM
15JYP2
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
41811
TABLE 18SUMMARY OF PREVIOUSLY FINALIZED POLICIES FOR PUBLIC REPORTING ON PHYSICIAN COMPAREContinued
Data
collection
year
2015 ...........
2015 ...........
2015 ...........
2015 ...........
2015 ...........
2015 ...........
2015 ...........
QCDR ............................
Reporting mechanism(s)
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00127
Fmt 4701
Sfmt 4702
E:\FR\FM\15JYP2.SGM
15JYP2
41812
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00128
Fmt 4701
Sfmt 4702
E:\FR\FM\15JYP2.SGM
15JYP2
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00129
Fmt 4701
Sfmt 4702
41813
E:\FR\FM\15JYP2.SGM
15JYP2
41814
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
TABLE 19SUMMARY OF PROPOSED MEASURE AND PARTICIPATION DATA FOR PUBLIC REPORTING
Data collection
year *
Publication
year *
Data type
Reporting mechanism
2016 ..................
2017
PQRS, PQRS,
GPRO, EHR, and
Million Hearts.
2016 ..................
2018
2016 ..................
2017
PQRS, PQRS,
GPRO.
PQRS, GPRO ........
2016 ..................
2017
ACO .......................
2016 ..................
2017
2016 ..................
2017
PQRS .....................
2016 ..................
2016 ..................
2017
2017
QCDR ...................................
Claims ..................................
2016 ..................
2017
PQRS, PQRS,
GPRO.
* Note that these data are proposed to be reported annually. The table only provides the first year in which these proposals would begin on an
annual basis, and such dates also serve to illustrate the data collection year in relation to the publication year. Therefore, after 2016, 2017 data
would be publicly reported in 2018, 2018 data would be publicly reported in 2019, etc.
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00130
Fmt 4701
Sfmt 4702
E:\FR\FM\15JYP2.SGM
15JYP2
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
4. Seeking Public Comment for Possible
Future Rulemaking
a. Quality Measures
In addition to these proposals, we
seek comment on several new data
elements for possible inclusion on the
individual EP and group profile pages of
Physician Compare. In future years, we
will consider expanding public
reporting to include additional quality
measures. We know there are gaps in
the measures currently available for
public reporting on Physician Compare.
Understanding this, we would like to
hear from stakeholders about the types
of quality measures that will help us fill
these gaps and meet the needs of
consumers and stakeholders. Therefore,
we seek comment on potential measures
that would benefit future public
reporting on Physician Compare. We are
working to identify possible data
sources and we seek comment on the
measure concepts, as well as potential
specific measures of interest. The
quality measures that would be
considered for future posting on
Physician Compare are those that have
been comprehensively vetted and
tested, and are trusted by the physician
community.
b. Medicare Advantage
We also seek comment on adding
Medicare Advantage information to
Physician Compare individual EP and
group practice profile pages.
Specifically, we are seeking comment
on adding information on the relevant
EP and group practice profile pages
about which Medicare Advantage health
plans the EP or group accepts and
making this information a link to more
information about that plan on the
Medicare.gov Plan Finder Web site. An
increasing number of Medicare
clinicians provide services via Medicare
Advantage. Medicare Advantage quality
data is reported via Plan Finder at the
plan level. As a result, physicians and
other health care professionals who
participate in Medicare Advantage do
not have quality measure data available
for public reporting on Physician
Compare. Adding a link between
Physician Compare clinicians
participating in Medicare Advantage
plans and the associated quality data
available for those plans on Plan Finder
ensures that consumers have access to
all of the quality data available to make
an informed health care decision.
c. Value Modifier
We also seek comment on including
additional VM cost and quality data on
Physician Compare. Specifically, we
seek comment on including in future
VerDate Sep<11>2014
Jkt 235001
41815
e. Measure Stratification
Finally, we seek comment on
including individual EP and group
practice-level quality measure data
stratified by race, ethnicity, and gender
on Physician Compare, if feasible and
PO 00000
Frm 00131
Fmt 4701
Sfmt 4702
E:\FR\FM\15JYP2.SGM
15JYP2
41816
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00132
Fmt 4701
Sfmt 4702
E:\FR\FM\15JYP2.SGM
15JYP2
Federal Register / Vol. 80, No. 135 / Wednesday, July 15, 2015 / Proposed Rules
VerDate Sep<11>2014
Jkt 235001
PO 00000
Frm 00133
Fmt 4701
Sfmt 4702
41817
E:\FR\FM\15JYP2.SGM
15JYP2